Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.
https://european-biotechnology.com/wp-content/uploads/2024/04/csm_carsten-thiel_f88a4077c6.jpg282282h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-03 11:00:512018-04-03 11:00:51Abeona Therapeutics Appoints Carsten Thiel as CEO
Motif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in high-risk MRSA (Methicillin-resistant S. aureus) patients.
https://european-biotechnology.com/wp-content/uploads/2024/04/Ebi_3fra_deposited_chain_front_image-800x800.png800800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-03 08:26:332018-04-03 08:26:33Motif Bio to submit NDA for iclaprim
https://european-biotechnology.com/wp-content/uploads/2024/04/tk_11_2017_ute_kilger_16x9.jpg293520h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-01 14:42:002018-04-01 14:42:00Balancing generic and innovative medical uses
Rentschler Biopharma SE announced today that Dr. Thomas Rösch will join the Company as Vice President Biopharma Engineering & Technology, effective April 1, 2018. He will be responsible for advanced biopharmaceutical engineering projects to enhance site and capacity.
https://european-biotechnology.com/wp-content/uploads/2024/04/RentschlerBiopharma_ThomasRoesch.jpg400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-03-29 10:51:392018-03-29 10:51:39Rentschler appoints Dr. Thomas Rösch
Japanese drug giant Takeda Pharmaceutical Co. Ltd. has confirmed its intention to make a bid for orphan drug leader and neurology specialist Shire plc. The take-over offer has to be made until 25 April.
https://european-biotechnology.com/wp-content/uploads/2024/04/shire_HAE.jpg388513Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-29 08:58:482018-03-29 08:58:48Takeda announced bid for Shire
Roche’s US arm Genentech has confirmed a total of 5 deaths in adult patients who were dosed with its to-be hemophilia blockbuster emicizumab (Hemlibra), a BITE antibody that mimics the effect of Factor VIII which lack patients with hemophilia A.
More than 400 experts came together at the World Bio Market Conference in Amsterdam to discuss the challenges of successfully implementing bio-based business strategies.
Belgian nanobody maker Ablynx’ IL-6 receptor blocker vobarilizumab didn’t met the primary endpoint of dose response at 24 weeks in a Phase II study enroling 312 patients with severe, active seropositive systemic lupus erythematosus (SLE).
Antibody specialist MorphoSys AG has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed Nasdaq offering of American Depositary Shares (ADS)
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Spring_2018_SPENNEMANN__Christoph_tg.jpg440780h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-03-23 00:40:002018-03-23 00:40:00We need creative investment to tackle AMR
Abeona Therapeutics Appoints Carsten Thiel as CEO
AppointmentsAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.
Motif Bio to submit NDA for iclaprim
Latest NewsMotif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in high-risk MRSA (Methicillin-resistant S. aureus) patients.
Balancing generic and innovative medical uses
OpinionIs cheaper always better when it comes to generics? What about when it comes to innovative medical uses of them?
Rentschler appoints Dr. Thomas Rösch
AppointmentsRentschler Biopharma SE announced today that Dr. Thomas Rösch will join the Company as Vice President Biopharma Engineering & Technology, effective April 1, 2018. He will be responsible for advanced biopharmaceutical engineering projects to enhance site and capacity.
Takeda announced bid for Shire
Latest NewsJapanese drug giant Takeda Pharmaceutical Co. Ltd. has confirmed its intention to make a bid for orphan drug leader and neurology specialist Shire plc. The take-over offer has to be made until 25 April.
Roche reports 5 deaths after dosing of Hemlibra
Latest NewsRoche’s US arm Genentech has confirmed a total of 5 deaths in adult patients who were dosed with its
to-be hemophilia blockbuster emicizumab (Hemlibra), a BITE antibody that mimics the effect of Factor VIII which lack patients with hemophilia A.
From biorefineries to consumer goods
Latest NewsMore than 400 experts came together at the World Bio Market Conference in Amsterdam to discuss the challenges of successfully implementing bio-based business strategies.
Ablynx’ SLE antibody vobarilizumab miss endpoint
Latest NewsBelgian nanobody maker Ablynx’ IL-6 receptor blocker vobarilizumab didn’t met the primary endpoint of dose response at 24 weeks in a Phase II study enroling 312 patients with severe, active seropositive systemic lupus erythematosus (SLE).
MorphoSys files registration for ADS offering
Latest NewsAntibody specialist MorphoSys AG has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed Nasdaq offering of American Depositary Shares (ADS)
We need creative investment to tackle AMR
Opinion